RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--PharmaLinkFHI, Inc. (PharmaLink) announced today that it has appointed Frank Santoro, MD as Chief Medical Officer. Dr. Santoro joins PharmaLink from Protherics, a UK-based biopharmaceutical company specializing in oncology and critical care products where he served as Vice President, Clinical Development and Medical Affairs. In that capacity, he provided medical oversight and clinical study management for the company’s clinical development programs. Prior to Protherics, Dr. Santoro worked in the Contract Research Organization (CRO) industry for more than seventeen years in positions of increasing responsibility, including ClinTrials Research, Innovex, Kendle International and Covance, where he built medical and clinical capabilities to service client’s development programs. He has extensive experience managing global operations having directed global project management, clinical monitoring, pharmacovigilence, regulatory and biometric services. During his career, Dr. Santoro has served as project physician for more than 100 domestic and international studies, and directed project team activities for numerous multi-therapeutic Phase I-IV research programs.
